Archive for COPD

Syntrix Receives $3.8M Grant to Develop New Treatment for COPD and Lung Disease Affecting Newborns

Congratulations to Syntrix scientists on their new grant for $3.8M from the National Hearth Lung and Blood Institute (NHBLI) of the National Institutes of Health (NIH). The project title is “Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD.” Here is the public health relevance from the proposal: “Pulmonary inflammatory diseases such as bronchopulmonary dysplasia (BPD) […]

Syntrix Reports the Cellular Mechanism of Compounds It Discovered to Treat COPD and Lung Disease in Neonates

Congratulations to Syntrix scientists and their collaborators at Montana State University on their latest publication in The Journal of Pharmacology and Experimental Therapeutics. Signficance: These studies demonstrate that compounds discovered by Syntrix to treat COPD and lung disease in neonates work by inhibiting CXCR1/2, G-protein coupled receptors, via a novel intracellular mechanism. Abstract: The chemokine receptors CXCR1/2 are […]